Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: mlkr who wrote (2923)	6/11/2010 4:37:36 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MRNA has 4Qs of much lower revenues after selling its intranasal business.<g> Although it still was able to trim some its loss on the 1stQ compared to 2009, there was a significant sequential increase when compared to the 4thQ results. The revenue results won't look as bad by comparison in the 2ndQ and further Qs, Still the L for the Yr. is expected to be > double the $0.22 loss in 2009. The LTD isn't bad, but at the rate it has been burning its cash, it will need further financing. Today it closed up 2% on volume about 1/10 its ADV. And a 2% gain isn't bad/<g> As we have commented many times, if one could average 2% net gain on a weekly basis, one should more than double the stake in a year's time.<g> The ACTAY is $2.67 which would be > 100% gain from present levels.<g> MRNA on Wednesday announced that it obtained exclusive rights to Unlocked Nucleobase Analog based diagnostics from RiboTask, a privately held Denmark-based company. With this expansion of its previous agreement with RiboTask and combining it with the previously acquired rights to technology for both therapeutics and diagnostics, MDRNA has now established one of the few intellectual property portfolios with the ability to pursue proprietary nucleic acid-based therapeutics and diagnostics. The stock has closed its Jan13 spike, which had a H of $1.87 But because of the large negative CF, and other considerations, I think I will just keep a target at $1.40 bigcharts.marketwatch.com Bernard